Results 291 to 300 of about 2,830,257 (398)

Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real‐life multicenter study

Headache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary This study shows that galcanezumab is equally effective and well‐tolerated in patients aged 65 and older as in younger patients, with a higher proportion of excellent responders in older patients. Despite having more baseline headache days, older patients responded well to the treatment, with age being linked to better outcomes ...
Julia Peris‐Subiza, Víctor Obach, Daniel Guisado‐Alonso, Fernando Velasco Juanes, Rocío Álvarez Escudero, María Martín Bujanda, Sonsoles Aranceta, Aintzine Ruisánchez, Natalia Roncero, Ane Mínguez‐Olaondo, Amaya Echeverria, Alba López‐Bravo, Ángel Luis Guerrero‐Peral, David García‐Azorín, Elisa Cuadrado‐Godia, Galca‐Only Study Group, Neus Fabregat, Marta Ruibal, Izaro Kortazar Zubizarreta, Nuria Riesco, Lucia González‐Fernández, Paula Manera, Agustín Oterino Duran, Yésica González‐Osorio, Santiago Fernández‐Fernández, Juan Carlos García‐Moncó, Isabel Fernández‐Pérez, Joan Jiménez‐Balado   +27 more
wiley   +1 more source

Single-Nucleus Transcriptomics Reveals Glial Metabolic-Immune Rewiring and Intercellular Signaling Disruption in Chronic Migraine. [PDF]

Biomolecules
Hu S, Tang Z, Sun S, Liu L, Wang Y, Xu L, Yuan J, Chen Y, Sun M, Zhao L.   +9 more
europepmc   +1 more source

Building a national headache medicine research network: The BE WELL with Migraine Champion Providers Network™

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective Our objective was to develop and assess the effectiveness of a national network of clinicians referring adults with migraine for a remotely delivered clinical trial. Background A national practice‐based research network in Headache Medicine would facilitate referrals into clinical trials.
Rebecca Erwin Wells, Junelyn Floyd, Hannah O'Brien, Nicole Tamol, Caroline Oliver, Camden Nelson, Joshua Phillips, Paige M. Estave, Shivani Vaidya, Brian Moore, Katherine Hamilton, Ellie Adam, Nathaniel O'Connell, Justin B. Moore, Richard B. Lipton, Timothy T. Houle, Zev Schuman‐Olivier, Paula Gardiner, Scott W. Powers, on behalf of the BE WELL with Migraine Champion Providers Network™, Abigail Anderson, Stephanie Ausborn, Marius Birlea, Robert Bonakdar, Susan Broner, Rebecca Burch, Larry Charleston, Michelle Clementi, Carrie Dougherty, Annika Ehrlich, Christopher Gottschalk, Laura Granetzke, Samantha Irwin, Crystal Jicha, Katie Johnson, Shirley Kessel, Sandhya Kumar, Deena Kuruvilla, Morris Levin, Andrew Maier, Brittany Mays, Gretchen Michaelson, Tesha Monteith, Andrea Murphy, Barbara Nye, Hope O’Brien, Brian Plato, Kristyn Pocock, Melissa Rayhill, Beth Robertson, Aysha Siddika, Amaal Starling, Lauren Strauss, Danielle Wilhour, Laura Xanders, Derek Yuan   +55 more
wiley   +1 more source

Real-world treatment chronic migraine in Poland. [PDF]

Arch Med Sci
Domitrz I, Karaszewski B, Stępień A.
europepmc   +1 more source

The Efficacy of response-based imagery strategies in the treatment of chronic migraine/tension headache.

, 1989
Amber Hayward
openalex   +2 more sources

Can atogepant be a preventive treatment for cluster headache?—Insights from a case series

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Cluster headache (CH) is a disabling primary headache disorder with limited therapeutic options. Calcitonin gene‐related peptide (CGRP) is known to be involved in CH pathophysiology; however, except for galcanezumab (300 mg) in episodic CH, anti‐CGRP monoclonal antibodies did not reduce CH attacks in randomized clinical trials. Atogepant is an
Catarina Serrão, Filipa Dourado Sotero, Linda Azevedo Kauppila, Isabel Pavão Martins   +3 more
wiley   +1 more source

Translational Impact of Genetics and Epigenetics of CGRP System on Chronic Migraine Treatment with Onabotulinumtoxin A and Other Biotech Drugs. [PDF]

Toxins (Basel)
Scuteri D, Martelletti P.
europepmc   +1 more source

Three years of remote electrical neuromodulation (REN) acute treatment for migraine shows consistent effectiveness and no tachyphylaxis phenomenon

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective The current study aimed to evaluate the remote electrical neuromodulation (REN) wearable device over 3 years, assessing the potential for tachyphylaxis, consistent effectiveness, overall utilization patterns, and safety. Background Migraine is a highly prevalent chronic neurological disease, especially during peak years of ...
Stephanie J. Nahas, Marius Birlea, Alit Stark‐Inbar, Sharon Shmuely, Eden Mama, Alon Ironi, William B. Young, Alan M. Rapoport   +7 more
wiley   +1 more source

Safety of Onabotulinumtoxin-A for Chronic Migraine During Pregnancy and Breastfeeding: A Narrative Review. [PDF]

Toxins (Basel)
Russo A, Iannone LF, Orologio I, Rivi V, Boccalini A, Lo Castro F, Silvestro M, Guerzoni S.   +7 more
europepmc   +1 more source